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Abstract
Background: There is convincing evidence from numerous clinical and epidemiological studies that physical activity can
reduce the risk for breast and prostate cancer. The biological mechanisms underlying this phenomenon remain elusive.
Herein we suggest a role for naturally produced antibodies reactive with the vasoactive intestinal peptide (VIP) in the
suppression of breast and prostate cancer, which we believe could offer a possible molecular mechanism underlying control
of these cancers by physical exercise.
Methodology and Results: We found that sera from individuals having breast and prostate cancers have decreased titers of
VIP natural antibodies as demonstrated by a lower reactivity against peptide NTM1, having similar informational and
structural properties as VIP. In contrast, sera collected from elite athletes, exhibited titers of natural NTM1-reactive
antibodies that are significantly increased, suggesting that physical activity boosts production of these antibodies.
Significance: Presented results suggest that physical exercise stimulates production of natural anti-VIP antibodies and likely
results in suppression of VIP. This, in turn, may play a protective role against breast and prostate cancers. Physical exercise
should be further investigated as a potential tool in the treatment of these diseases.
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Introduction
The vasoactive intestinal peptide (VIP) is a pleiotropic peptide
important in many physiologic functions, including glucose
homeostasis, neuroprotection, memory, gut function, modulation
of the immune system and circadian function. In addition, there are
numerous evidences that (VIP) and its receptors, which are highly
expressed in breast tumor cells [1],[2],[3],[4],[5],[6],[7],[8], play an
important role inthepathogenesis ofbreastcancer.VIPfunctions as
an autocrine growth factor [8],[9] and regulates proliferation,
survival, and differentiation in human breast cancer cells [10]; it has
proangiogenic functions [11] in breast cancer. VIP also induces
transactivation of epidermal growth factor receptor (EGFR) and
human epidermal growth factor-2 receptor (HER2) and increases
expression of c-fos, c-jun and c-myc oncogenes [2],[12],[13]. There
alsois mountingevidencethat VIP is involved inthe pathogenesisof
prostate cancer. VIP increases the expression of the major
angiogenic factor VEGF [14] and acts as a proangiogenic factor
[15],[16],[17]. VIP increases neuroendocrine differentiation [18]
and stimulates interleukin-6 production [19] and prostate-specific
antigen (PSA) secretion in prostate cancer [20]. In addition, VIP
stimulates HER2 transphosphorylation in androgen-independent
prostate cancer cells [17], stimulates their invasive capacity [21] and
contributes to prostate cancer pathogenesis by induction of
malignant transformation [22]. VIP antagonists suppress the release
of prostate-specific antigen (PSA) [23] and inhibit growth of breast
and prostate cancer cells [24],[25],[26],[27],[28],[29].
Taken together, these observations strongly support the notion
that VIP plays an important role in breast and prostate cancer
pathogenesis and suggests that elevated concentrations of VIP in
the circulation may represent a risk factor for these cancer types.
VIP is elevated in plasma after aerobic exercise [30],31[31],
[32],[33],[34],[35],[36] suggesting that physical activity represents
a potential stimulus for VIP autoantibody formation [37],[38].
Because of the immunomodulatory and neuromodulatory activ-
ities of VIP, circulating levels of this peptide are under tight control
and natural anti VIP autoantibodies are potent modifiers of its
biological actions and important regulators of its circulating level
[39],[40],[41],[42],[43]. However, the antigenic stimulus leading
to the formation of these autoantibodies has not been identified
yet. It was previously shown that structural and informational
similarity, represented by the informational spectrum frequencies,
is essential for the immunological cross-reactivity between VIP and
HIV-1 gp120 [44],[45],[46],[47]. This analysis revealed that
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derived peptide resembling informational and structural properties
of VIP [48].
The present study was carried out in order to compare reactivity
with peptide NTM1 of sera collected from individuals with breast
and prostate cancer and sera from elite athletes. Obtained results
showed a significant difference in NTM1 reactivity of sera from
elite athletes, healthy controls and cancer patients.
Results
Reactivity of sera collected from subjects with breast and
prostate cancer with peptide (NTM1s)4-SOC4 was determined by
the ELISA immunoassay (Figure 1 and Table 1). Statistical
analysis revealed that this reactivity in sera from cancer patients
was significantly lower in comparison with the reactivity of control
sera P(0.02) and P(3.7e-05) in breast and prostate cancer,
respectively). In Table 2 is given the total IgG content determined
for breast and prostate cancer patients.
In Figure 1 and Table 1 are presented the results of ELISA
testing of sera collected from elite athletes. Analysis showed that
(NTM1s)4-SOC4-reactivity of sera from elite athletes was highly
significantly different (i) from reactivity of sera collected from
healthy, sedentary controls (for female: swimming P(2.9e-06),
water polo P(0.0001), volleyball P(8.1e-07), all female elite athletes
P(2e-6); for male: rowing P(1.8e-06), wrestling P(0.0009), karate
P(3.2e-07), all male elite athletes P(2e-6)), and (ii) from sera from
cancer patients (for breast cancer: swimming P(1.2e-05), water
polo P(4.1e-6), volleyball P(7.1e-06), all female elite athletes P(2e-
6); for prostate cancer: rowing P(1.8e-06), wrestling P(1.2e-5),
karate P(6.4e-07), all female elite athletes (2e-9).
Discussion
There is now strong and consistent evidence from several studies
conducted worldwide that regular physical activity reduces breast
cancer risk by 20% to 30% and that a dose–response effect exists
[49]. Long-term athletic training during the college and pre-
college years lowers the risk of breast cancer throughout the life
span [50],[51],[52]. For tertiary cancer prevention, observational
studies suggest that breast cancer survivors performing exercise
(e.g., 2–3 h of brisk walking/week) have a 40–67% reduction in
breast cancer recurrence and all-cause mortality compared with
inactive survivors [53],[54],[55]. Similar data were reported for
prostate cancer where an average risk reduction ranged from
10%–30% [56],[57]. Recently, the evaluation of physical activity
in relationship to prostate cancer mortality among 2,750 men
diagnosed with prostate cancer showed that a modest amount of
vigorous activity, such as biking, tennis, jogging, or swimming for
3 hours a week, may substantially improve prostate cancer-specific
survival [58],[59].
However, the potential biologic mechanisms through which
physical activity may decrease the risk of breast and prostate cancer
are still elusive. Several putative etiologic pathways, including those
involving steroid hormones, chronic inflammation, growth factors,
lymphokines and insulin resistance were suggested (reviewed in Ref.
[49]). On the other hand, there are mounting evidences that VIP
pathway plays an important role in pathogenesis of breast and
prostate cancer, indicating that elevated concentration of VIP, a
facilitator of breast and prostate cancer, in the circulation may
contribute to these diseases and that suppression of this peptide
could have positive effect [24],[25],[26],[27],[28],[29].
The level of circulating VIP is controlled by natural anti-VIP
antibodies [39],[40],[41],[42],[43] and we hypothesized that these
suppressive antibodies could contribute to a better control of breast
and prostate cancer and that lack of these antibodies could
contribute to the progression of these diseases. In order to test this
assumption we compared reactivity with peptide NTM1 of sera
collected from cancer patients and healthy control. Results given in
Table1and Figure1showthatthisreactivityissignificantlylowerin
cancer patients in comparison with healthy control subjects.
Paul and Said showed that natural anti-VIP antibodies were
present in plasma from 29.6% of healthy human subjects who
habitually performed aerobic muscular exercise (running, cycling,
swimming, aerobic dancing, and/or weight training, 3 or more
workouts per week for a year or more prior to study entry),
compared to 2.3% of healthy subjects who did not [37]. Herein,
Figure 1. Results of ELISA. The absorbance values (OD) obtained for
sera of cancer patients, athletes and healthy control subjects with
peptide NTM1. Antibodies recognizing peptide NTM1 are significantly
more prevalent in serum samples from athletes compared to control
subjects (swimming P(2.9e-06), water polo P(0.0001), volleyball P(8.1e-
07), rowing P(1.8e-06), wrestling P(0.0009), and karate P(3.2e-07); Mann-
Whitney test). The absorbance values for sera from cancer patients are
significantly lower in comparison with the values obtained for control
sera (P(0.02) and P(3.7e-05) in breast and prostate cancer, respectively;
Mann-Whitney test).
doi:10.1371/journal.pone.0028304.g001
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trained athletes had increased titers of NTM1 reactive antibodies,
23 out of 28 (82.1%) females and 23 out of 26 (88.5%) males
compared to non-athletes. This finding expanded our recent
report on male water polo elite athletes [38] and strongly
supported the suggestion that physical exercise represents a
stimulus of the immune system which boosts production of natural
VIP/NTM1-reactive antibodies.
The total IgG content in all cancer patients (1162.7 mg/ml)
and in elite athletes (11.262.9 mg/ml) was in the normal range
(7–16 mg/ml) and comparable with normal values suggesting that
that difference in the different age distribution of the athletic
subjects (18–26) and cancer patients (5663.9) did not significantly
affect global function of the immune system, allowing comparison
of immunological data obtained for these two studied groups.
Thus, the reduced levels of natural antibodies recognizing peptide
NTM1 in breast and prostate patients was specific and may
contribute to disease progression.
The antigenic stimulus for the formation of natural VIP/NTM1-
reactive antibodies could not be identified from our studies;
however, several studies have demonstrated that acute exercise is
associated with increased plasma levels of VIP [30],[31],[32],
[33],[34],[35],[36]. It is thus plausible to theorize that these
antibodies may have been produced in response to an increase in
VIP levels during exercise, providing increased antigenic stimulus.
In line with this hypothesis is that physical activity provides a
potentialsource ofthe naturalanti-VIP/NTMantibodiesthat could
contribute to the control of breast and prostate cancer.
In order to keep the conclusions derived from this study under
its real extent, it is necessary take into account that elite athletes
are different from sedentary and even from physically active
subjects, not just because of the exercise routine, but mainly for
genetic predisposition allowing remarkable physiological and
biological indexes. For this reason, we can’t exclude the possibility
that these specific genetic makeup of elite athletes could also
partially contribute to their increased production of natural VIP/
NTM1-reactive antibodies.
Herein we suggest a possible role for naturally produced
antibodies reacting with peptides VIP and NTM1 in the control of
breast and prostate cancer, which we believe could offer a possible
molecular mechanism underlying positive effects of physical
exercise in these cancers. Presented results strongly suggest further
research of physical exercise as an important natural approach
against breast and prostate cancer. Because little is known about
the optimal level of exercise in combating of these cancers,
variations in the mode, intensity, duration, and frequency of
exercise prescriptions also requires future research.
Materials and Methods
Ethics statement
Informed consent and local ethics committee approval was
obtained for these human studies. All patients provided written
informed consent. The Ethical Committee for Clinical Trials of
the Faculty of Pharmacy in Belgrade is responsible for the ethical
conduct of this study.
Human subjects
Cancer patients. Sera samples were collected from 15
subjects with breast and 17 subjects with prostate cancer (disease
stage, values of tumor markers and the age are given in Table 2).
Sera were collected immediately after confirmed diagnosis and
before the start of any therapeutic intervention.
Athletic subjects. Sera samples were collected from 54
Serbian elite international athletes (26 males and 28 females)
engaged in the following types of sports activities: wrestling, water
polo, rowing, karate, kick boxing, swimming and volleyball.
Female and male elite athletes were engaged in the sport training
in average 9 and 11 years, respectively. All athletes were tested at
the end of basic preparatory mezocycle (a phase of training with
duration of between 4–6 weeks) in a period of recuperative
microcycle (shorter training period of about 7–10 days for active
recuperation of the athletes) [60]. We expected that in this latter
period, production of natural antibodies which clear VIP from
circulation should have reached higher levels.
Controls. Sera samples were collected from 34 healthy (HIV-
negative) individuals (17 males and 17 females) doing sedentary
computer work 6–8 h a day and who were not performing regular
physical exercise (healthy, sedentary subjects). The ages of all
controls (18–26) matched the athletic subjects and there were no
risk factors that would affect the immune system (cigarette smoke,
alcohol consumption, use of medications, chronic diseases, etc).
Peptide conjugates synthesis
The synthesis of the (NTM1s)4-SOC4 conjugate was carried out
manually by stepwise solid phase peptide synthesis using the Boc-
Gly-OCH2-Pam resin (1 g, 0.25 mmol/g capacity). Sequential
oligopeptide carrier (SOC4), formed by the repetitive Lys-Aib-Gly,
is applied to display analyzed peptides. The synthetic procedure
starts with the step-by-step couplings of the protected residues
(Boc/Bzl) corresponding to the SOC4 carrier to the resin. Lysine
was introduced as Boc-Lys(Fmoc)-OH. After removal of the Fmoc
protective groups from the Lys-N
eH2 groups by 20% piperidine in
dimethylformamide, synthesis of the epitope FTDNAKTI was
carried out (Boc/Bzl) by the simultaneous attachment of each
residue in four copies.
ELISA
ELISA was performed with peptide (NTM1s)4-SOC4 by the
following procedure: polystyrene microtest plates (Sarstedt,
Germany) were incubated overnight at 4uC with 100 mlo f
Table 1. Comparison of the reactivity with peptide NTM1 of
sera from cancer patients, athletes and healthy control
subjects.
Tested
population
Number of
subjects Gender O.D. (mean) O.D. (± s.d.)
Cancer patients
Breast cancer 15 F 0.021 0.011
Prostate cancer 17 M 0.022 0.014
Athletes
Swimming 7 F 0.269 0.074
Water polo 8 F 0.171 0.105
Volleyball 13 F 0.104 0.033
Rowing 8 M 0.131 0.046
Wrestling 9 M 0.106 0.054
Karate 9 M 0.108 0.020
Controls
17 F 0.041 0.025
17 M 0.046 0.016
doi:10.1371/journal.pone.0028304.t001
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were washed with phosphate-buffered saline (PBS)–0.05% Tween
and non-specific sites were blocked with 200 ml PBS containing
5% bovine serum albumin (BSA) for 2 h at room temperature.
After six washings, serum specimens were added to the wells
(100 ml/well). Sera were diluted 1:100 in 5% BSA in PBS. Plates
were incubated for 3 h at room temperature. After six washings
with PBS–0.05% Tween, 100 ml of goat anti-human IgG alkaline
phoshatase-conjugated antibodies (Sigma), diluted 1:2500 were
added and the plates were incubated for 30 minutes at room
temperature. After six washings, pNPP (p-Nitrophenyl Phosphate)
substrate was added and the absorbance (OD) measured at 492–
620 nm after 15 minutes. Each sample was tested independently
twice and the mean values are reported.
Statistical analysis
The significance of the differences in O.D. values for individuals
with breast and prostate cancer, elite athletes and control subjects
was calculated by the non-parametrical Kruskal-Wallis. The two
groups are unpaired with uneven variance and therefore they were
considered as part of a two-tailed, heteroscedastic matrix. For each
comparison, the level of significance p for a directional test is
given.
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Table 2. Data for investigated breast and prostate cancer patients and the absorbance values obtained for their sera with peptide
NTM1.
Patient Type of cancer Disease stage Age Tumor marker
* Total IgG [g/l] NTM1 (OD)
P1 breast III 42 49.4 13.9 0,016
P2 breast IV 59 104.9 12.9 0,016
P3 breast IV 61 74.7 9.2 0,032
P4 breast II 39 43.4 11.5 0,006
P5 breast IV 49 99.8 9.8 0,028
P6 breast IV 47 172 11.2 0,024
P7 breast IV 55 98.7 11.4 0,035
P8 breast II 36 36.4 6.0 0,034
P9 breast IV 49 2533 12.6 0,032
P10 breast III 51 54.5 8.0 0,036
P11 breast IV 52 366 16.4 0,014
P12 breast III 56 64 9.0 0,008
P13 breast IV 63 199 10.7 0,025
P51 breast IV 59 1014 13.0 0,009
P207 breast IV 64 186 12.0 0,008
P1 prostate IV 60 238,0 11,4 0,020
P2 prostate III 56 31,1 9,95 0,016
P3 prostate IV 62 47,0 12,4 0,025
P9 prostate II 48 17,1 16,9 0,027
P69 prostate III 59 40,5 8,41 0,007
P105 prostate II 50 18,3 14,2 0,015
P179 prostate III 62 22,2 11,4 0,023
P182 prostate II 48 12,7 14,7 0,020
P8 prostate IV 66 150,0 16,4 0,016
P94 prostate IV 72 249,9 16,5 0,044
P76 prostate III 58 32,6 11,4 0,050
P356 prostate II 52 13,5 12,1 0,011
P344 prostate IV 69 49,5 14,9 0,035
P55 prostate IV 64 58,6 14,28 0,042
P120 prostate IV 68 154,0 16,3 0,006
P222 prostate III 54 21,9 13,6 0,011
P318 prostate IV 70 280,0 10,1 0,003
*Tumor markers: breast cancer (CA15-3); prostate cancer (PSA).
doi:10.1371/journal.pone.0028304.t002
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